No-Reflow Phenomenon

01/01/2002 - "The reasons for early preventive use of intracoronary introduction of verapamil and other drugs in the presence of risk of development of no-reflow phenomenon are presented. "
06/01/1994 - "In a prior small series of cases, this "no-reflow" phenomenon appeared to be promptly reversed by the intra-coronary administration of verapamil. "
01/01/2013 - "In conclusion, the no-reflow phenomenon following primary PCI in patients with STEMI is significantly improved by intracoronary administration of verapamil which is useful to reduce cardiovascular events during operation."
11/01/2002 - "Treatment of no-reflow phenomenon with verapamil after primary stent deployment during myocardial infarction."
09/01/2001 - "[Treatment of no-reflow phenomenon with intracoronary verapamil after primary stent deployment during myocardial infarction]."

12/01/2022 - "The frequency of no-reflow phenomenon was lower in the adenosine group as assessed by TIMI flow grade (15 [14%] vs. 41 [35%]), MBG (23 [21%] vs. 63 [53%]) and TIMI frame count (16 [14%] vs. 50 [42%]) (p < .001 for all). "
12/01/2022 - "We aimed to determine the effect of intracoronary adenosine in preventing the no-reflow phenomenon, as detected by three different methods, in patients who underwent primary (PCI). "
01/01/2014 - "Intracoronary adenosine administered during aortocoronary vein graft interventions may reduce the incidence of no-reflow phenomenon. "
10/01/2001 - "Use of intracoronary adenosine for the management of slow-no-reflow phenomenon during percutaneous interventions."
12/01/2000 - "Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon."

03/01/2000 - "CONCLUSION: In this small nonrandomized study significant improvement in coronary flow was achieved by using intravenous abciximab after observing slow flow or no reflow phenomenon during primary PTCA. "
12/01/2000 - "Some studies have reported improved coronary flow after abciximab in slow or no-reflow phenomenon. "
01/01/2008 - "'Rescue' administration of abciximab is an effective option for the treatment of the no-reflow phenomenon determining significant prognostic improvements."
01/01/2008 - "We retrospectively selected 38 patients who developed the no-reflow phenomenon after primary angioplasty: 18 received post-procedural abciximab, 20 age- and sex-matched patients who did not receive abciximab were considered as concurrent controls. "
01/01/2008 - "We sought to investigate the effect of post-procedural abciximab on clinical outcome of patients presenting the no-reflow phenomenon after primary angioplasty. "

10/01/2010 - "Treatment of an Angioguard XP filter with a urokinase solution is effective in preventing pore occlusion and may reduce occurrence of the slow-flow phenomenon."
06/01/1989 - "In order to evaluate the effect of fibrinolytic drugs on the "no reflow" phenomenon, urokinase was infused prior to reperfusion, and after 5 hours of ischemia, in a separate group of animals. "
12/01/1996 - "In a patient with a complicated history of coronary artery disease, a restenotic lesion inside a Gianturco-Roubin flex stent was relieved by angioplasty and deployment of three 10 mm Palmaz P-104 "biliary" stents, with urokinase and verapamil used to prevent thromboembolism and the no-reflow phenomenon. "
03/01/1987 - "We compared the efficacy of intra-arterial infusion of urokinase, a fibrinolytic agent, with that of intra-arterial infusion of nitrendipine, a peripheral calcium-channel blocking agent, in preventing the no-reflow phenomenon in rats after prolonged ischemia at room temperature. "

04/01/2012 - "In addition, the coronary angiography both in the first and second event demonstrated coronary slow flow phenomenon, which improved after the intracoronary administration of nicorandil. "
11/01/2020 - "Trial sequential analysis confirmed the effect of nicorandil in reducing the incidence of no-reflow phenomenon and follow-up major adverse cardiovascular events in patients with AMI after PCI. "
12/01/2002 - "The purpose of this study was to evaluate the effect of nicorandil on no-reflow/slow flow phenomenon during RA procedures. "
03/31/2022 - "The results show that nicorandil can significantly improve the no-reflow phenomenon in AMI patients during PCI."
01/01/2007 - "We report a case of coronary slow flow phenomenon induced after contrast injection which was resolved by nicorandil administration. "

03/16/2004 - "Sodium nitroprusside is one of several agents considered effective for treating the no-reflow phenomenon during acute coronary interventions. "
10/01/2004 - "Intracoronary bolus injection of nitroprusside using a 3 ml syringe appears to be a feasible, safe, and effective technique for the management of slow/no-reflow phenomenon complicating primary PCI."
11/20/2009 - "This study aimed to evaluate intracoronary nitroprusside in the prevention of the no-reflow phenomenon in AMI. "
11/20/2009 - "Intracoronary nitroprusside can improve myocardial microcirculation, leading to the decrease of the incidence of no-reflow phenomenon and better prognosis."
01/01/2014 - "The objective of this study was to evaluate the clinical efficacy and safety of nitroprusside injection for preventing the slow-flow/no-reflow phenomenon after percutaneous coronary intervention (PCI). "

01/01/2023 - "Results from available evidence suggest that IC epinephrine might be an effective and safe agent in managing the no-reflow phenomenon."
02/19/2015 - "Among those, 12 patients which received intracoronary epinephrine to treat a refractory no-reflow phenomenon were evaluated. "
01/01/2023 - "To assess the efficacy and safety of intracoronary (IC) epinephrine in the management of no-reflow phenomenon following percutaneous coronary intervention (PCI), either as first-line treatment or after the failure of conventional agents. "
01/01/2023 - "Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study."
03/01/2022 - "During primary PCI, intracoronary epinephrine is as effective as adenosine in successful management of refractory no-reflow phenomenon with a more favorable long-term prognosis compared to adenosine. "

01/01/2019 - "Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? "
11/01/1985 - "Preischemic perfusion washout with an acellular physiologic solution delays the no-reflow phenomenon and improves tissue survival in rat epigastric free flaps following 18 and 24 hours of normothermic ischemia. "
10/01/2010 - "Treatment of an Angioguard XP filter with a urokinase solution is effective in preventing pore occlusion and may reduce occurrence of the slow-flow phenomenon."
01/01/2021 - "Perforated balloon technique mediated intracoronary delivery of nicorandil to treat coronary no-reflow phenomenon: a novel pharmacological solution to precarious situation."
11/01/1993 - "The most effective protection against a no-reflow phenomenon, however, is flushing the nutrient vessels with a heparin solution."

09/01/1978 - "The poor survival results in the SH group; two of 12 are attributed to the low oxygen availability possibly triggering the no-reflow phenomenon which prevents reversibility of the myocardial ultrastructural damage and ultimately the functional integrity of the ventricle."
09/01/1978 - "The effect of blood oxygen content and the no-reflow phenomenon on the subendocardial ultrastructural reversibility following anoxic arrest using hemodilution variables in the experimental model."
11/01/1993 - "Although some cellular function can proceed via anaerobic mechanisms, a point is reached at which restoration of blood flow and oxygen delivery does not result in restoration of function ("refractory shock" or the "no-reflow phenomenon"). "
08/01/2008 - "Organs procured from brain-dead hyperbaric oxygen-treated donors may have less cellular injury from ischemia, reperfusion, and no-reflow phenomenon, thus yielding organs in an optimized state for transplantation. "
06/17/1994 - "Functional assessment of the efficacy of oxygen free radical scavengers in the "no-reflow" phenomenon in skeletal muscle."

04/01/2001 - "The objective of this study was to test the hypothesis that the intracoronary administration of a direct donor of nitric oxide is a safe and effective method to treat impaired blood flow (no-reflow phenomenon) that occurs during percutaneous transluminal coronary interventions (PTCI). "
05/01/2014 - "The role of nitric oxide in the coronary slow flow phenomenon."
01/01/2020 - "The aim of the present study was to examine the association between 2 polymorphisms of the endothelial nitric oxide (eNOS) gene (-786T>C and +894G>T) and the no-reflow/slow-flow phenomenon in post-primary percutaneous coronary intervention (PPCI) patients. "
06/01/2003 - "The reduced availability of nitric oxide leads to the adhesion of neutrophils to the vascular endothelium, platelet aggregation and, with the contribution of endothelin, vasoconstriction, which are responsible for the "no-reflow" phenomenon. "

01/01/2022 - "No-reflow phenomenon after primary percutaneous coronary intervention is a common condition affecting the outcomes; therefore, studying its predictive factors is helpful in identifying patients at high risk. "
10/15/2004 - "This device brought about a significant reduction in the no-reflow phenomenon and improvement in ST resolution compared with conventional percutaneous coronary intervention."
06/01/2008 - "Efficacy of culprit plaque assessment by 64-slice multidetector computed tomography to predict transient no-reflow phenomenon during percutaneous coronary intervention."
11/01/2023 - "In our previous study, the PIANO score was constructed to predict the occurrence of no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention (PCI). "
11/01/2019 - "In the present study, we analysed the incidence of no-reflow phenomenon, its clinical and procedural predictors, and associated in-hospital outcomes for the patients undergoing primary percutaneous coronary intervention (PCI). "

01/01/2017 - "A number of studies have explored therapy for this unique pathophysiology since the first report on "no-reflow phenomenon" was published roughly 50 years ago. "
08/01/1996 - "In this study, several pharmacologic agents were utilized individually or in combination therapy as postischemic washouts, in an effort to attack the multiple causative factors in the no-reflow phenomenon and to improve flap survival in a rat abdominal skin flap model. "
06/08/2023 - "A systematic literature review and a meta-analysis of clinical data on definition, rates, and impact of the no-reflow phenomenon after reperfusion therapy was carried out. "
02/10/2023 - "Objective :To investigate the predictive value of no reflow phenomenon in interventional therapy by measuring plaque quantitatively with optical coherence tomography (OCT). "
01/01/2022 - "The optimum therapy for coronary slow flow phenomenon (CSFP) stays debatable. "

01/01/2022 - "This study aimed to evaluate whether prolonged balloon inflation in stent deployment would lessen the occurrence of the no-reflow phenomenon in PPCI compared with conventional rapid inflation/deflation strategy. "
10/12/2023 - "Prediction of Slow-Flow Phenomenon After Stent Implantation Using Near-Infrared Spectroscopy in Patients With Acute and Chronic Coronary Syndrome."
01/01/2023 - "An unusual no-reflow phenomenon due to neointimal tissue embolization during drug eluting balloon intervention in stent restenosis: A case report."
10/01/2022 - "We advocated the utility of modest stent expansion strategy, which was defined as the stent (or post-balloon) diameter-to-culprit vessel diameter ratio < 0.71, for prevention of slow flow phenomenon. "
10/01/2022 - "Our group showed that the stent (or post-balloon) diameter-to-vessel diameter ratio was inversely associated with slow flow phenomenon. "

08/25/1998 - "Rotational atherectomy with the Rotablator catheter has improved percutaneous treatment of certain coronary atherosclerotic lesions, but the "no-reflow" phenomenon remains a serious complication. "
02/01/2011 - "How to manage no reflow phenomenon with local drug delivery via a rapid exchange catheter."
03/01/2010 - "The twin-pass dual access catheter for assessment of the no-reflow phenomenon."
12/01/2006 - "As soon as the diagnosis of "no reflow phenomenon" was confirmed, an intra-arterial catheter was fixed. "
05/24/2006 - "We describe two cases in which the no-reflow phenomenon developed during PCI and was successfully resolved by direct intracoronary aspiration using the Export aspiration catheter."

12/01/2006 - "Through our series of fifteen digital replantations, having suffered a "no reflow phenomenon", we are going to present the fibrinolytic protocol we used and the promising results we obtained. "
12/01/2006 - "The success rate is very encouraging (80%) and it turns this protocol into a precious ally of the digit replantation microsurgery and an effective therapeutic means way against the "no reflow phenomenon"."
10/01/1992 - "The no-reflow phenomenon is one of the factors that increase morbidity in flap and replantation surgery. "
05/01/1983 - "Although further studies are necessary for clinical application, it is suggested that the FC immersion technique has a definite potential for prevention of the no-reflow phenomenon in tissue transplantation and replantation surgery."
03/01/2010 - "Among the relative contraindications to replantation are prolonged warm ischaemia time, since an obstruction to blood reflow ('no-reflow phenomenon') may occur in amputated parts that are subjected to more than 6h of warm ischaemia. "